Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose pegylated interferon alfa-2a plus ribavirin in HIV/HCV coinfected adults with HCV genotypes 2 or 3
2007-000814-35Phase 4Active
- Sponsor
- Luis Fernando López Cortés
- Start
- Oct 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by Luis Fernando López Cortés. Primary endpoints: Sustained virologic response, Rapid virologic response and 2 more. Started Oct 2007; status: active.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2007-000814-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000814-35.